Q32 Bio Inc.

Filed a patent for "targeted treatment of complement-mediated disease through local complement inhibition based on urinary uc5b-9 detection" on Mon, July 17, 2023

Filed a patent for "adeno-associated virus compositions for arsa gene transfer and methods of use thereof" on Wed, August 10, 2022

Filed a patent for "non-naturally occurring polyadenylation elements and methods of use thereof" on Thu, April 13, 2023

Filed a patent for "adeno-associated virus compositions for arsa gene transfer and methods of use thereof" on Tue, October 18, 2022

Filed a patent for "methods and compositions for the purification of adeno-associated virus" on Thu, June 15, 2023

Filed a patent for "methods and compositions for the purification of adeno-associated virus" on Thu, June 15, 2023

Filed a patent for "methods and compositions for the production of adeno-associated virus" on Thu, September 7, 2023

Filed a patent for "methods and compositions for the production of adeno-associated virus" on Thu, October 12, 2023

Filed a patent for "adeno-associated virus compositions for arsa gene transfer and methods of use thereof" on Fri, February 3, 2023

Filed a patent for "liver de-targeted recombinant aav capsid proteins" on Fri, March 3, 2023

Filed a patent for "bidirectional dual promoter expression vectors and uses thereof" on Thu, November 23, 2023

Filed a patent for "adeno-associated virus packaging systems" on Thu, February 23, 2023

Filed a patent for "adeno-associated virus packaging systems" on Thu, February 9, 2023

Filed a patent for "adeno-associated virus formulations" on Thu, March 9, 2023

Filed a patent for "adeno-associated virus formulations" on Thu, March 23, 2023